BioreclamationIVT acquires Asterand Bioscience

Published: 11-Aug-2017

The acquisition broadens BioreclamationIVT’s disease state biospecimen capabilities, particularly in oncology and expands its scientific service offerings for diagnostic and drug development researchers

BioreclamationIVT, provider of biospecimens and related services, has acquired Asterand Bioscience, a global provider of high quality, well characterised human tissue and research solutions with a focus on the oncology market.

Asterand Bioscience advances drug research by accelerating target identification, biomarker validation and improving drug candidate selection to increase the likelihood of clinical success.

Jeff Gatz, CEO of BioreclamationIVT, said: “We are delighted Asterand Bioscience’s talented staff is joining BioreclamationIVT. This is a great fit between two complementary companies. This acquisition will expand BioreclamationIVT’s portfolio of highly annotated disease state biospecimens.

"After combining Asterand Bioscience’s first rate oncology tissue sourcing network with our existing strength in procuring disease state tissue and clinical biofluids, BioreclamationIVT will become the market leader in disease state biospecimens and a top resource for researchers focused on precision medicine.

"The addition of Asterand Bioscience’s tissue services and PhaseZERO research services groups will allow the combined company to offer a full research workflow solution, ranging from specimen sourcing through experimental design to data collection. BioreclamationIVT’s new offerings will include target and biomarker validation using histology and molecular techniques, and compound evaluation using cell-based model systems.”


You may also like